Molnupiravir Demonstrates 77% Efficacy Against Feline Infectious Peritonitis in Clinical Trial
Key Insights
Colorado State University researchers found molnupiravir achieved 77% survival rates in 73 cats with naturally occurring FIP (search) during a 12-week treatment trial.
The antiviral provides a second treatment option alongside GS-441524, particularly for cats who don't respond to or relapse after initial therapy.
Side effects were manageable and did not require treatment discontinuation, with 12% of survivors experiencing relapse but surviving after additional treatment.
Colorado State University veterinarians have demonstrated that molnupiravir, an antiviral medication, achieves 77% effectiveness against feline infectious peritonitis (search) (FIP (search)), providing a crucial second treatment option for a disease that was historically fatal in cats.
Clinical Trial Results
The clinical trial at CSU's Veterinary Hospital enrolled 73 cats with naturally occurring FIP (search), with treatment administered orally twice daily for 12 weeks followed by regular checkups for six months. The study achieved a 77% survival rate, with 12% of surviving cats experiencing relapse but ultimately surviving after undergoing another round of treatment.
Side effects observed during the trial included constipation, diarrhea, hypersalivation, nausea, vomiting, reduced appetite, pruritus, folded ears, elevated ALT, and neutropenia. Importantly, none of the cats experienced side effects severe enough to require discontinuation of the medication.
Expanding Treatment Options
The research establishes molnupiravir as a viable alternative to GS-441524, which demonstrates roughly 80% effectiveness against FIP (search). While GS-441524 may remain the primary treatment choice, molnupiravir offers veterinarians options for cats who fail to respond to GS-441524, stop responding to it, or experience relapse. Like GS-441524, veterinarians can prescribe molnupiravir from compounding pharmacies.
GS-441524, which was recently legalized in the United States after years of restricted access, requires an 84-day treatment regimen administered either by injection or oral form. The medication has transformed the treatment landscape for a disease that veterinarians previously considered a death sentence.
Disease Characteristics and Impact
FIP (search) presents in two main forms - dry and wet - each with distinct symptom profiles, and can also manifest as ocular and neurological complications. Dry FIP symptoms include fever, rapid weight loss, lethargy, and vision issues, while wet FIP may present with distended belly, lethargy, and severe breathing difficulties.
The disease, caused by feline coronavirus (search), shares similarities with severe coronavirus infections in humans. Researchers are investigating whether FIP (search) survivors experience long-term symptoms similar to long COVID, with findings potentially offering insights applicable to human health.
Future Research Directions
Additional research is underway to evaluate other potential treatments, including Paxlovid, for FIP (search) management. The ongoing studies on FIP in cats may provide valuable insights that could benefit both veterinary and human medicine, given the similarities between feline coronavirus (search) and human coronavirus infections.
After completing treatment, cats are considered in remission and monitored for an additional 84 days before being cleared from FIP (search). The availability of multiple treatment options represents a significant advancement in veterinary medicine for a condition that previously offered no hope for affected cats and their owners.